In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus

Session The right glucose-lowering drugs for the right patient

Speaker David Berg

Event : ESC Congress 2019

  • Topic : preventive cardiology
  • Sub-topic : Diabetes and the Heart: Pharmacotherapy
  • Session type : Advances in Science

Authors : D Berg (Boston,US), S Wiviott (Boston,US), B Scirica (Boston,US), Y Gurmu (Boston,US), O Mosenzon (Jerusalem,IL), S Murphy (Boston,US), D Bhatt (Boston,US), L Leiter (Toronto,CA), D Mcguire (Dallas,US), J Wilding (Liverpool,GB), P Johansson (Goteborg,SE), A Langkilde (Goteborg,SE), I Raz (Jerusalem,IL), E Braunwald (Boston,US), M Sabatine (Boston,US)

D. Berg1 , S. Wiviott1 , B. Scirica1 , Y. Gurmu1 , O. Mosenzon2 , S. Murphy1 , D. Bhatt1 , L. Leiter3 , D. McGuire4 , J. Wilding5 , P. Johansson6 , A. Langkilde6 , I. Raz2 , E. Braunwald1 , M. Sabatine1 , 1Brigham and Womens Hospital - Boston - United States of America , 2Hadassah University Medical Center - Jerusalem - Israel , 3St. Michael's Hospital - Toronto - Canada , 4University of Texas Southwestern Medical School - Dallas - United States of America , 5Aintree University Hospital - Liverpool - United Kingdom , 6AstraZeneca - Goteborg - Sweden ,

European Heart Journal ( 2019 ) 40 ( Supplement ), 153

Background: Patients with type 2 diabetes mellitus (T2DM) are at increased risk of developing heart failure (HF). Treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors reduces the risk of hospitalization for HF (HHF) in patients with T2DM.

Purpose: To develop and validate a practical, multivariable clinical risk score for HHF in patients with T2DM and assess whether this score can identify high-risk patients with T2DM who have the greatest reduction in risk for HHF with an SGLT2 inhibitor.

Methods: We developed a clinical risk score for centrally-adjudicated HHF using independent clinical risk indicators of HHF in 8212 patients with T2DM in the placebo arm of SAVOR-TIMI 53. Candidate variables were assessed using multivariable Cox regression and independent clinical risk indicators achieving statistical significance of p<0.001 were included in the risk score and given weights proportional to the regression coefficients. We externally validated the score in 8578 patients with T2DM in the placebo arm of DECLARE-TIMI 58. Discrimination was assessed using Harrell's c-index. The relative and absolute risk reductions in HHF with the SGLT2 inhibitor dapagliflozin were assessed by baseline HHF risk.

Results: The 5 independent clinical risk indicators were prior heart failure, atrial fibrillation, coronary artery disease, estimated glomerular filtration rate (eGFR), and urine albumin/creatinine ratio (UACR) (Figure, left). A simple integer-based scheme using these predictors identified a strong >16-fold gradient of HHF risk (p-trend <0.001) in both the derivation and validation cohorts, with c-indices of 0.81 and 0.78, respectively. Whereas relative risk reductions were similar across the risk score (25–34%), absolute risk reductions were greater in those at higher baseline risk (interaction p-value for absolute risk reduction <0.01), with high-risk (2 points) and very high-risk patients (≥3 points) having 1.5% and 2.7% absolute risk reductions in HHF at 4 years with dapagliflozin, translating into NNTs of only 65 and 36, respectively (Figure, right).

Conclusion(s): Risk stratification using a novel clinical risk score for HHF in patients with T2DM identifies patients at higher risk for HHF who derive greater benefit from treatment with the SGLT2 inhibitor dapagliflozin.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are